 Biotechnology player Longeveron Inc. LGVN , Financial more than doubled in value from a single trading session after a major U.S. FDA announcement. The clinical-stage biotech player, which is engaged in research and development using stem cell research to develop therapies to combat heart diseases, aging, frailty, Alzheimers disease and other neurological disorders, recently received an encouraging update from the FDA in regards to one of its treatments, marking a key step on the path to profitability. 